Literature DB >> 26525506

Methodological approach to brain derived neurotrophic factor in children with autism spectrum disorder.

Mehmet Agilli1, Fevzi N Aydin2, Tuncer Cayci3, Yasemin G Kurt3.   

Abstract

Entities:  

Year:  2015        PMID: 26525506      PMCID: PMC4627192          DOI: 10.5214/ans.0972.7531.220416

Source DB:  PubMed          Journal:  Ann Neurosci        ISSN: 0972-7531


× No keyword cloud information.
Dear Editor, In a recent issue of Annals of Neurosciences, we read with great interest the article by Kasarpalkar and colleagues entitled “Brain-Derived Neurotrophic Factor in children with Autism Spectrum Disorder” in which the investigators reported that the protective effect of brain derived neurotrophic factor (BDNF) due to relatively higher levels in mild phenotypes of autism compared to severe autism and its possible diagnostic role in autism spectrum disorders.[1] However, we think that some points should be discussed. BDNF is signaling protein that involved in the central regulation of energy homeostasis. Maffioletti and colleagues reported that serum preparation procedure is quite important issue to present robust methodology while measuring serum BDNF.[2] BDNF level is presumably affected from duration of the clotting procedure due to being stored in thrombocytes. They observed progression on serum BDNF concentrations, which reached 38% of the plateau value after 10 min, 91.8% after 30 min, and 100% after 1 hour. Therefore, they recommended the minimum clotting duration for a correct serum BDNF dosage as 1 hour. However, in this study, the authors stated that serum samples were separated immediately after blood was collected. We think that standardization of clotting process is highly important to prevent misinterpretation of serum BDNF levels. Previous studies suggested that certain diseases such as epilepsy, allergic rhinitis and atopic dermatitis could likely affect BDNF levels.[3] In addition, medications such as aspirin and corticosteroids, and dietary supplements such as vitamin E, vitamin A, vitamin B12, folic acid, zinc, omega-3 fatty acids, and ginkgo biloba extracts can influence BDNF levels.[4-6] In this regard, without defining these contributing factors, interpreting the results is problematic. The authors did not express any of above contributors. In conclusion, clarifying these concerns will certainly provide a clearer picture when interpreting serum BDNF levels among participants.
  6 in total

1.  Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum.

Authors:  Elisabetta Maffioletti; Roberta Zanardini; Massimo Gennarelli; Luisella Bocchio-Chiavetto
Journal:  Biotechniques       Date:  2014       Impact factor: 1.993

2.  Differential effect of clopidogrel and aspirin on the release of BDNF from platelets.

Authors:  Paul Stoll; Annett Plessow; Kai Bratke; J Christian Virchow; Marek Lommatzsch
Journal:  J Neuroimmunol       Date:  2011-07-31       Impact factor: 3.478

Review 3.  Brain-derived neurotrophic factor.

Authors:  Devin K Binder; Helen E Scharfman
Journal:  Growth Factors       Date:  2004-09       Impact factor: 2.511

4.  Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus.

Authors:  M A Smith; S Makino; R Kvetnansky; R M Post
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

5.  Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial.

Authors:  Zahra Solati; Shima Jazayeri; Mehdi Tehrani-Doost; Salma Mahmoodianfard; Mahmood Reza Gohari
Journal:  Nutr Neurosci       Date:  2014-01-07       Impact factor: 4.994

6.  Brain-Derived Neurotrophic Factor in children with Autism Spectrum Disorder.

Authors:  Nikhil J Kasarpalkar; Sweta T Kothari; Usha P Dave
Journal:  Ann Neurosci       Date:  2014-10
  6 in total
  1 in total

1.  Expression Analysis of BDNF, BACE1, and Their Natural Occurring Antisenses in Autistic Patients.

Authors:  Soudeh Ghafouri-Fard; Amir Namvar; Shahram Arsang-Jang; Alireza Komaki; Mohammad Taheri
Journal:  J Mol Neurosci       Date:  2019-11-23       Impact factor: 3.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.